UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
June
12, 2008
Commission
File Number:
000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
711
Executive Blvd., Suite Q
Valley
Cottage, New York 10989
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F
x
Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
o
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o
No
x
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
|
|
|
XTL
BIOPHARMACEUTICALS LTD.
|
|
|
|
|
Date:
June 12, 2008
|
By:
|
/s/
Ron
Bentsur
|
|
|
Ron
Bentsur
|
|
|
Chief
Executive Officer
|
EXHIBIT
INDEX
|
|
Exhibit
|
|
|
|
Number
|
Description
|
|
|
|
|
|
|
99.1
|
Press
Release dated June 11, 2008.
|
|
|
|
|
|
|
99.2
|
Notice
of Annual General Meeting and Notice of Extraordinary General
Meeting
|
|
|
|
|
|
|
99.3
|
Form
of Proxy for use at the Annual General Meeting and Extraordinary
General Meeting of the Company to be held on July 17,
2008
|
|
|
|
|
|
|
99.4
|
Press
Release dated June 12, 2008
|